Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

NCT05839119 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Principal Investigator left institution

Conditions

Urothelial Carcinoma Bladder
Androgen Receptor Positive

Interventions

DRUG: Degarelix
COMBINATION_PRODUCT: Gemcitabine/Cisplatin

Sponsor

Brown University

Collaborators

[object Object]
[object Object]
[object Object]